INDIANAPOLIS — A new study published in the Journal of the American Medical Association shows that tirzepatide, the active ingredient in Eli Lilly’s weight‑loss medication Zepbound, produced a substantial drop in body‑mass index (BMI) among teenagers. The trial, presented at ObesityWeek, involved 160 participants ages 12 to 17 who were classified as obese or overweight with at least one related health condition.
Study design and results
Researchers compared weekly tirzepatide injections with a placebo. After 72 weeks, the tirzepatide group saw an average BMI reduction of 18.5%, while the placebo group experienced a 0.5% increase. The trial was conducted at 31 medical‑research centers and hospitals across the United States and five additional countries.
Side‑effects and safety
The most common adverse events were gastrointestinal—nausea, vomiting and diarrhea—most of which were described as mild to moderate. No new safety concerns were identified beyond what is already known about the medication.
Local relevance
Eli Lilly, headquartered in Indianapolis, funded the study. The company’s involvement underscores the city’s role in advancing medical research that could benefit families nationwide. For Indiana parents concerned about teen health, the findings suggest a potential new tool, pending further regulatory review.
Expert commentary
Aaron Kelly, a professor of pediatrics at the University of Minnesota and the study’s corresponding author, said the data “could help expand treatment options for adolescents dealing with obesity.” He emphasized that the drug is not yet approved for teen use; the FDA currently limits Zepbound to adult patients.
What’s next?
Regulatory officials will need to evaluate the trial’s safety and efficacy data before considering an extension of the drug’s label to younger patients. If approved, tirzepatide could become a valuable addition to the limited arsenal of pediatric obesity therapies, aligning with broader public‑health goals to curb childhood obesity rates.
Community impact
Local health providers and school‑based wellness programs may soon have a new evidence‑based option to discuss with families. The study’s positive outcomes also highlight the importance of continued research funding, a cause that resonates with Indiana’s tradition of supporting medical innovation.
Original reporting: WOWO News/Talk (Fort Wayne) — read the source article.